Mark Novas

2.3k total citations · 1 hit paper
24 papers, 1.5k citations indexed

About

Mark Novas is a scholar working on Pathology and Forensic Medicine, Oncology and Ecology, Evolution, Behavior and Systematics. According to data from OpenAlex, Mark Novas has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 4 papers in Ecology, Evolution, Behavior and Systematics. Recurrent topics in Mark Novas's work include Multiple Sclerosis Research Studies (13 papers), Fungal Plant Pathogen Control (4 papers) and Polyomavirus and related diseases (4 papers). Mark Novas is often cited by papers focused on Multiple Sclerosis Research Studies (13 papers), Fungal Plant Pathogen Control (4 papers) and Polyomavirus and related diseases (4 papers). Mark Novas collaborates with scholars based in United States, Czechia and Germany. Mark Novas's co-authors include Robert J. Fox, J. Theodore Phillips, Eva Havrdová, Katherine Dawson, Vissia Viglietta, Mariko Kita, Michael Hutchinson, Marianne T. Sweetser, David H. Miller and Minhua Yang and has published in prestigious journals such as New England Journal of Medicine, Neurology and Journal of the Neurological Sciences.

In The Last Decade

Mark Novas

22 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

2012 1.0k citations Robert J. Fox, David H. Miller et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Novas United States	8	1.1k	424	327	317	313	24	1.5k
Kartik Raghupathi United States	9	1.1k 1.0×	417 1.0×	371 1.1×	399 1.3×	642 2.1×	22	2.0k
Małgorzata Leyk United States	5	1.4k 1.2×	354 0.8×	473 1.4×	907 2.9×	286 0.9×	8	2.0k
Alexander Korn Germany	14	406 0.4×	152 0.4×	148 0.5×	642 2.0×	93 0.3×	41	1.5k
Paul Frohna United States	17	204 0.2×	171 0.4×	125 0.4×	403 1.3×	99 0.3×	47	1.3k
Roberto Bomprezzi United States	12	239 0.2×	123 0.3×	127 0.4×	396 1.2×	106 0.3×	24	973
Sara Rollinson United Kingdom	13	93 0.1×	257 0.6×	372 1.1×	824 2.6×	187 0.6×	20	1.6k
Batia Kaplan Israel	22	201 0.2×	148 0.3×	135 0.4×	665 2.1×	190 0.6×	66	1.2k
Judith F. Ashouri United States	13	132 0.1×	187 0.4×	70 0.2×	207 0.7×	128 0.4×	18	941
Catherine Rehder United States	24	209 0.2×	216 0.5×	48 0.1×	572 1.8×	384 1.2×	75	1.9k
Carlos R. Ferreira United States	22	135 0.1×	92 0.2×	71 0.2×	970 3.1×	300 1.0×	101	2.1k

Countries citing papers authored by Mark Novas

Since Specialization

Citations

This map shows the geographic impact of Mark Novas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Novas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Novas more than expected).

Fields of papers citing papers by Mark Novas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Novas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Novas. The network helps show where Mark Novas may publish in the future.

Co-authorship network of co-authors of Mark Novas

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Novas. A scholar is included among the top collaborators of Mark Novas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Novas. Mark Novas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Giacco, Antonia, et al.. (2024). Infusion of Del Nido Cardioplegia Prior to Donor Heart Implantation Minimizes Severe Primary Graft Dysfunction After Heart Transplantation. The Journal of Heart and Lung Transplantation. 43(4). S581–S581.

Calkwood, Jonathan, Timothy Vollmer, Robert J. Fox, et al.. (2015). Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. International Journal of MS Care. 18(3). 138–146. 7 indexed citations

Pozzilli, Carlo, J. Theodore Phillips, Robert J. Fox, et al.. (2015). Long-term Follow-up of the Safety of Delayed-Release Dimethyl Fumarate in RRMS: Interim Results from the ENDORSE Extension Study. (P7.235). Neurology. 84(14_supplement). 5 indexed citations

Li, Jie, Ralf Gold, Robert J. Fox, et al.. (2015). Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience (P7.238). Neurology. 84(14_supplement). 4 indexed citations

Gold, Ralf, J. Theodore Phillips, Eva Havrdová, et al.. (2015). Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and Therapy. 4(2). 93–104. 67 indexed citations

Phillips, J. Theodore, Krzysztof Selmaj, Ralf Gold, et al.. (2015). Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. International Journal of MS Care. 17(5). 236–243. 49 indexed citations

Fox, Robert J., Krzysztof Selmaj, Ray Zhang, et al.. (2014). Safety Profile of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis (RRMS): Long-term Interim Results From the ENDORSE Extension Study (P2.200). Neurology. 82(10_supplement). 2 indexed citations

Viglietta, Vissia, Timothy R. Vollmer, Ray Zhang, et al.. (2014). Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered as Add-On Therapy to Beta Interferons or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (I7-2.003). Neurology. 82(10_supplement). 1 indexed citations

Viglietta, Vissia, Timothy R. Vollmer, Ray Zhang, et al.. (2014). Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered as Add-On Therapy to Beta Interferons or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (S4.002). Neurology. 82(10_supplement). 1 indexed citations

10.

Hutchinson, Michael, J. Theodore Phillips, D. H. Miller, et al.. (2013). Efficacy and Safety of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis in the Phase 3 CONFIRM Study. UCL Discovery (University College London). 1 indexed citations

11.

Sheikh, Sarah, Ivan Nestorov, John O’Gorman, et al.. (2013). Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers. Clinical Therapeutics. 35(10). 1582–1594.e9. 48 indexed citations

12.

Hutchinson, Michael, Robert J. Fox, David H. Miller, et al.. (2013). Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Journal of Neurology. 260(9). 2286–2296. 74 indexed citations

13.

Meltzer, Leslie, Krzysztof Selmaj, Ralf Gold, et al.. (2013). Gastrointestinal Tolerability Events in Relapsing–Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral BG-12 (Dimethyl Fumarate) in DEFINE and CONFIRM (P01.164). Neurology. 80(7_supplement). 3 indexed citations

14.

Selmaj, Krzysztof, J. Theodore Phillips, Robert J. Fox, et al.. (2013). Safety and tolerability of BG-12 (dimethyl fumarate) in relapsing–/INS;remitting multiple sclerosis: Interim results from the endorse extension study. Journal of the Neurological Sciences. 333. e367–e368.

15.

Gold, Ralf, J. Theodore Phillips, Eva Havrdová, et al.. (2013). BG-12 (Dimethyl Fumarate) and Pregnancy: Preclinical and Clinical Data from the Clinical Development Program (P02.129). Neurology. 80(7_supplement). 8 indexed citations

16.

Gold, Ralf, Eva Havrdová, Amit Bar‐Or, et al.. (2013). BG-12 (dimethyl fumarate) and pregnancy: Preclinical studies and pregnancy outcomes reported during the clinical development program. Journal of the Neurological Sciences. 333. e382–e382. 3 indexed citations

17.

Fox, Robert J., Mariko Kita, Stanley Cohan, et al.. (2013). BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Current Medical Research and Opinion. 30(2). 251–262. 86 indexed citations

18.

Hutchinson, Michael, D. H. Miller, J. Theodore Phillips, et al.. (2012). Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study. UCL Discovery (University College London). 2 indexed citations

19.

Havrdová, Eva, D. H. Miller, J. Theodore Phillips, et al.. (2012). Clinical and neuroimaging outcomes with BG-12 treatment in CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis), a multicenter, randomized, placebo-controlled, phase-3 study. UCL Discovery (University College London). 2 indexed citations

20.

Fox, Robert J., David H. Miller, J. Theodore Phillips, et al.. (2012). Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine. 367(12). 1087–1097. 1036 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact